Urinary F2-Isoprostanes and Metabolic Markers of Fat Oxidation

<table class="table-group" id="tab3"><tr><td><table class="table"><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr class="thead"><td align="left"> </td><td align="center">OR (95% CI)</td></tr><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr><td align="left">F2-isoprostane composite index</td><td align="center">0.51 (0.35, 0.76)</td></tr><tr><td align="left">Acetylcarnitine, C2 </td><td align="center">0.77 (0.60, 0.97) </td></tr><tr><td align="left">Valerylcarnitine, C5</td><td align="center">1.18 (0.92, 1.53)</td></tr><tr><td align="left">Dodecanoylcarnitine, C12 </td><td align="center">0.79 (0.62, 1.01)</td></tr><tr class="table-tr"><td colspan="2"><hr class="tbody-hr"/></td></tr></table></td></tr><tr class="table-fn"><td>ORs adjusted for age, gender, ethnicity, clinic and baseline BMI, and IGT-status and scaled to SD of F2-isoprostanes or acylcarnitines (log-transformed).<br/></td></tr></table>

Association of the baseline F2-isoprostane index and three selected acylcarnitines with incident type 2 diabetes (114 cases).

Oxidative Medicine and Cellular Longevity

tab3

Table 3

Table 3: Urinary F2-Isoprostanes and Metabolic Markers of Fat Oxidation 